Affiliation:
1. Virginia Commonwealth University
Abstract
Nirmatrelvir, the novel antiviral component of Pfizer’s orally available combination therapy Paxlovid, used to treat COVID-19, presents a significant synthetic challenge. Herein, we report process optimization insights that could enable a scalable and cost-effective manufacturing process to make nirmatrelvir. The disclosed development opens up a path to three new complete routes, offering options to eliminate some of the major cost-drivers for nirmatrelvir and deliver the final API in higher yield and lower overall cost while maintaining quality requirements.
Funder
Bill and Melinda Gates Foundation
Publisher
American Chemical Society (ACS)
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献